Targeting the EGFR/PCNA Signaling Suppresses Tumor Growth of Triple-Negative Breast Cancer Cells with Cell-Penetrating PCNA Peptides

ASIA unversity > 醫學暨健康學院 > 生物科技學系 > 期刊論文 > Item 310904400/64259

Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/64259

Title:	Targeting the EGFR/PCNA Signaling Suppresses Tumor Growth of Triple-Negative Breast Cancer Cells with Cell-Penetrating PCNA Peptides
Authors:	余永倫;Yu, Yung-luen;鄒瑞煌;Chou, Ruey-Hwang;Liang, JH;Liang, JH;Chang, WJ;Chang, WJ;Su, KJ;Su, KJ;Tseng, YJ;Tseng, YJ;Huang, WC;Huang, WC;Wang, SC;Wang, SC;洪明奇;Hung, Mien-Chie
Contributors:	生物科技學系
Keywords:	EPIDERMAL growth factor receptors;TYROSINE;GENE targeting;BREAST cancer;PHOSPHORYLATION;CANCER cells -- Proliferation;GENE expression;CELLULAR signal transduction
Date:	2013-04
Issue Date:	2013-10-29 02:55:12 (UTC+0)
Abstract:	Tyrosine 211 (Y211) phosphorylation of proliferation cell nuclear antigen (PCNA) coincides with pronounced cancer cell proliferation and correlates with poor survival of breast cancer patients. In epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-resistant cells, both nuclear EGFR (nEGFR) expression and PCNA Y211 phosphorylation are increased. Moreover, the resistance to EGFR TKI is a major clinical problem in treating EGFR-overexpressing triple-negative breast cancer (TNBC). Thus, effective treatment to combat resistance is urgently needed. Here, we show that treatment of cell-penetrating PCNA peptide (CPPP) inhibits growth and induces apoptosis of human TNBC cells. The Y211F CPPP specifically targets EGFR and competes directly for PCNA tyrosine Y211 phosphorylation and prevents nEGFR from binding PCNA in vivo; it also suppresses tumor growth by sensitizing EGFR TKI resistant cells, which have enhanced nEGFR function and abrogated classical EGFR membrane signaling. Furthermore, we identify an active motif of CPPP, RFLNFF (RF6 CPPP), which is necessary and sufficient to inhibit TKI-resistant TNBC cell growth of orthotopic implanted tumor in mice. Finally, the activity of its synthetic retro-inverted derivative, D-RF6 CPPP, on an equimolar basis, is more potent than RF6 CPPP. Our study reveals a drug candidate with translational potential for the future development of safe and effective therapeutic for EGFR TKI resistance in TNBC.
Relation:	PLoS One
Appears in Collections:	[生物科技學系] 期刊論文

Files in This Item:

File	Size	Format
index.html	0Kb	HTML	375	View/Open

Loading...